DoD Prostate Cancer, Physician Research Award | W81XWH 21 PCRP PRA

Opportunity Information: Apply for W81XWH 21 PCRP PRA

The FY21 DoD Prostate Cancer Research Program (PCRP) Physician Research Award is designed to help early-career physicians build a long-term, research-focused career in prostate cancer while they are still balancing real clinical responsibilities. It supports a mentored research experience where the physician applicant serves as the Principal Investigator (PI) and is expected to take primary ownership of the application itself, writing the proposal with guidance from one or more mentors. The program treats the science and the physician's career development as equally important, with the goal of producing clinicians who can become independent leaders in basic, translational, population science, or clinical prostate cancer research.

Eligibility is aimed at physicians at a specific transition point: applicants must have clinical duties and, by the submission deadline, must either be in the final year of an accredited residency or fellowship, or be within five years of starting a faculty appointment (including Instructor roles). A major intent of the award is to carve out protected research time so the PI can realistically develop as an investigator; the announcement strongly encourages applicants to show at least 40% protected time devoted to prostate cancer research. That protected effort does not have to be funded only by this award and can be combined with time supported by other prostate cancer research projects, but the application is expected to demonstrate that the PI will have meaningful, sustained time to do the work.

Mentorship is a required and central feature. Each application must include at least one designated mentor who has a clearly established track record in prostate cancer research, backed up by recent publications, active research funding, and evidence of successful mentorship. The mentor team is also expected to show a concrete commitment to advancing the PI's trajectory, not just providing technical oversight. If the research plan relies on resources, data, specimens, or specialized expertise at another institution, the opportunity encourages naming a co-mentor at that collaborating site to strengthen both the training environment and the feasibility of completing the project.

On the research side, proposed projects must address one or more of the FY21 PCRP Overarching Challenges, and the application is expected to present a thoughtful, well-justified rationale and a research strategy that shows deep understanding of the problem. Reviewers will be looking for a realistic, well-defined plan, including clear methods and milestones that demonstrate feasibility. Preliminary data can strengthen the case but is not required; if included, it must come from the PI, mentor(s), or members of the collaborating team. Applicants are also expected to identify the resources needed to execute the work and provide documentation to show those resources are truly accessible, often supported by letters confirming availability of data sets, repositories, specialized cores, or other key infrastructure.

A required component is an individualized Researcher Development Plan that explains how the PI will gain the skills and experience needed to complete the proposed research and progress toward independence. This plan should be tailored to the PI's background and gaps, and it should outline specific training strategies such as targeted coursework, technical training, structured mentorship meetings, networking, grant-writing experience, and opportunities to present and publish. The application must also describe the overall research and mentoring environment. If the home institution has limitations in mentorship or resources, the opportunity allows those gaps to be addressed through collaborations, provided the collaboration plan is clearly described and credible.

Impact is framed in program-level terms: the work should aim to solve an Overarching Challenge in a way that meaningfully advances the PCRP mission of eliminating death from prostate cancer and improving the well-being of Service Members, Veterans, and the broader community affected by the disease. To increase rigor and translational relevance, applicants are encouraged to build strong study-design practices into their proposals, such as authenticating cell lines, ensuring statistical rigor in animal studies, and including experiments that test clinical relevance and the potential for real-world translation. The announcement also encourages projects that leverage large patient cohorts, long-term health records, biospecimen repositories, and existing research resources, especially when paired with modern genomics/proteomics, bioinformatics, or advanced modeling approaches. Relevance to military populations is important, and collaborations between military or Veterans institutions and civilian institutions are strongly encouraged to take advantage of unique populations and infrastructure.

Human subjects research is allowed, but clinical trials are explicitly not permitted. The program does allow certain kinds of human research, including correlative studies connected to an existing clinical trial, as long as they are minimal risk and receive approval through the appropriate oversight channels. On the regulatory side, DoD-specific requirements apply: studies involving human subjects, human anatomical substances, or cadavers must be reviewed and approved by the USAMRDC Office of Research Protections Human Research Protection Office (HRPO) before the research can begin, in addition to local IRB or ethics review. Local IRB approval does not have to be in place at submission, but applicants are warned to plan for review timelines (often 2 to 3 months for HRPO). For multi-institution projects, a written plan for a single IRB arrangement is required, identifying the lead institution responsible for the master protocol and consent and serving as the central regulatory point of contact. Animal studies are also permitted, but they require DoD ACURO review in addition to local IACUC approval, and applicants should expect a longer timeline (often 3 to 4 months). The opportunity also emphasizes reproducibility and rigorous reporting, referencing widely used standards such as randomization, blinding, sample-size estimation, and ARRIVE guidelines for animal research.

Funding is provided through DoD assistance agreements, meaning awards will be made as either grants or cooperative agreements depending on how much substantial involvement the DoD anticipates during the project (for example, collaboration or participation in certain aspects of the work). The anticipated budget cap is $750,000 in direct costs for the full period of performance. Program leadership projected roughly $7.2 million total to fund about six awards, with selections based on scientific and programmatic review as well as availability of federal funds. The original application closing date listed for this opportunity was July 1, 2021, and awards were expected to be made no later than September 30, 2022, using FY21 funds that are available for use through September 30, 2027. The administering agency is the Department of Defense, Department of the Army (USAMRAA), under CFDA 12.420, and the opportunity number is W81XWH-21-PCRP-PRA.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Physician Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 05, 2021.
• Applicants must submit their applications by Jul 01, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PCRP PRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: